Telescope Innovations Corp. reported financial results for the full year ended August 31, 2025. The company generated revenues of CAD 5.8 million for the period. Expenses amounted to CAD 7.3 million. Telescope Innovations Corp. recorded an adjusted EBITDA loss of CAD 402 thousand for the fiscal year. Operational highlights for the period included continued progress on the multi-year funded project with Pfizer for Self-Driving Lab (SDL) development, deployment of the first SDL for pharmaceutical development in Korea in FY 2026, and the strongest sales performance to date for DirectInject-LC, including expansion in Europe and launch in Asia. The company also produced battery-grade lithium sulfide through its proprietary low-temperature method, with the first samples shipped to battery industry groups in North America and Asia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telescope Innovations Corp. published the original content used to generate this news brief on December 23, 2025, and is solely responsible for the information contained therein.